Gly-Low
Gly-Low. A five-component dietary combination aimed at methylglyoxal (MGO) and the advanced glycation end-product it forms, MG-H1. Its composition is stated verbatim…
A five-component dietary combination aimed at methylglyoxal (MGO) and the advanced glycation end-product it forms, MG-H1. Its composition is stated verbatim by the Cell Reports paper that reports its lifespan effect: "A combination of nicotinamide, alpha-lipoic acid, thiamine, pyridoxamine, and piperine (Gly-Low) lowers the deleterious effects of glycation by reducing MGO and the MGO-derived AGE, MG-H1, in mice" (PMID:41086114). The proposed mechanism for the food-intake and weight effects is not glycation-lowering directly but appetite signalling: "Gly-Low inhibits appetite stimulation through ghrelin and AMP-activated protein kinase (AMPK) signaling pathways in the hypothalamus, leading to reduced hunger responses." ALL PUBLISHED IN-VIVO WORK IS MOUSE. THIS IS A MIXTURE, NOT ONE MOLECULE, so it stores no molecular weight and no curve; the constituents carry their own records.
IDENTITY. Research name Gly-Low; the commercial name is GLYLO, disclosed in the Cell Reports conflict-of-interest statement — "L.A.W., N.B., and P.K. are patent holders of GLYLO, a supplement licensed to Juvify Bio by the Buck Institute. P.K. is the founder of Juvify Bio." That is recorded because the efficacy literature and the commercial interest share authors, which a reader should know. COMPOSITION IS NAMED BUT NOT PROPORTIONED. All five constituents are stated verbatim (PMID:41086114) and four of them are already in this catalog, but no fetched abstract gives a mg-per-gram or a per-ingredient dose, and composition[].mg_per_g_extract is a required positive number — so composition[] is deliberately NOT authored rather than filled with invented ratios. See the GAPS row. WHAT THE MOUSE DATA ACTUALLY SHOW, verbatim: survival — "increases survival in leptin receptor-deficient (Leprdb) and wild-type C57B6/J mice"; late-life dosing — "As a late-life intervention, Gly-Low slows hypothalamic aging signatures, improves glucose homeostasis and motor coordination, and increases lifespan" (both PMID:41086114). Vascular, from the published version of the aortic study (PMID:41247756): MGO "increased PWV in young mice by 21% (P<0.05 vs. control), which was prevented with Gly-Low (P=0.93 vs. control)". A CITATION DELIBERATELY NOT MADE: PMID:41045492 (Aging 2025, growth-hormone excess and liver glycation) surfaces in the same searches and is from the same programme, but its abstract does not mention Gly-Low at all, so it is not cited here. A PREPRINT IS NOT THE CITATION: the aortic study also exists as bioRxiv PMID:39829921, whose abstract words the same result as "old (24 month) mice"; the published paper (PMID:41247756) says "C57BL/6J (24 month) mice" instead — the published version is the one cited and the one quoted.
Sources: PMID:41086114, PMID:41247756, PMID:39829921